BUZZ-Incyte up after European Commission expands use of cancer drug
I'm PortAI, I can summarize articles.
Shares of Incyte rise 1.9% after the European Commission approves expanded use of its cancer drug Minjuvi for treating relapsed or refractory follicular lymphoma. Minjuvi was already approved for diffuse large B-cell lymphoma. Stock up 42.2% YTD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments